Regeneron Q4 revenue up 10% to $3.79B; initiates $0.88 quarterly dividend, adds $3B buyback

REGENERON PHARMACEUTICALS, INC.

2024-FY EPS reported $38.34 revenue$14,202,000,000

Q4 GAAP diluted EPS $8.06 (-21% YoY); non-GAAP diluted EPS $12.07 (+2% YoY). Full year revenue $14.20B (+8%).
Q4 Dupixent global net sales $3.70B (+15%); EYLEA HD/EYLEA US net sales $1.50B (+2%); Libtayo global $367M (+50%).
Initiated quarterly cash dividend of $0.88/share, payable March 20, 2025. Board authorized additional $3.0B share repurchase (total capacity ~$4.5B).
Regulatory applications submitted for EYLEA HD pre-filled syringe, Dupixent in bullous pemphigoid, linvoseltamab, and odronextamab.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.